MINISO Group Holding Ltd vs Smith & Nephew plc — how do they compare? MINISO Group Holding Ltd trades at $9.71 (market cap $2.65B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 4.2× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (7.34%). Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 25 Days and Smith & Nephew plc for 120 Days on average.
| MNSO | SNN | |
|---|---|---|
Market Cap | $2.65B | $11.10B |
Volume | 747,763 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $37.17 |
52-Week Low | $8.60 | $26.42 |
Typical Hold Time | 25 Days | 120 Days |
Enterprise Value | $3.52B | $14.13B |
Dividend Yield | 7.34% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $8.94, up 0.34% on the day, with a bearish technical signal from moving averages and a mixed earnings history. The company reported 2025 revenue of $21.44 billion and net income of $1.21 billion, with a P/E of 14.76 and P/S of 0.79 indicating reasonable valuation. Recent news highlights CFO share purchases and earnings volatility, with analyst consensus leaning bullish at 60% buy ratings.
The outlook for MNSO balances growth potential from domestic expansion against earnings inconsistency and competitive pressures. Investment appeal lies in its value metrics and operational scale, but risks include margin compression and market sentiment shifts. The stock's near-term direction hinges on sustained profitability improvements and macroeconomic conditions.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →